NCT04695327

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: TILT Biotherapeutics Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.

Detailed description

This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 as monotherapy in advanced solid tumor patients. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin 2. The trial includes 2 healthcare centers in Helsinki (Finland). Patients with different indications are expected to be treated in the trial.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	TILT-123	TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Timeline

• Start date: 2021-01-11
• Primary completion: 2025-09-03
• Completion: 2025-09-03
• First posted: 2021-01-05
• Last updated: 2026-03-06

Locations

2 sites across 1 country: Finland